PIL
08/12/2015 14:51
GENERAL
PRICE SENSITIVE
REL: 1451 HRS Promisia Integrative Limited
GENERAL: PIL: Arthrem(R) - Publication of positive clinical trial results
Mr Malcolm Johnson, chairman of Promisia Integrative Limited, announced today
publication of the positive clinical trial results for Arthrem(R) in the
management of symptoms of osteoarthritis. The results of the 12 week
randomised, placebo controlled trial have been published in the December
issue of the international peer reviewed journal, Clinical Rheumatology.
Promisia's principal scientist Dr Sheena Hunt explained: "The published
results show that the natural product, Arthrem(R), has potential as an
anti-inflammatory/analgesic in osteoarthritis. In patients taking Arthrem(R)
one capsule twice a day, pain and stiffness was significantly reduced and
physical function significantly improved. Particularly positive results were
observed in a subset of patients with mild to moderate osteoarthritis (as
opposed to severe osteoarthritis). In this subgroup, average magnitude of
pain after 12 weeks of taking Arthrem(R) was less than half of the value at
the start of the study. Arthrem(R) at this dose was also well tolerated with
no treatment-related side effects."
Chief executive officer Mr Charles Daily said: "We are extremely excited
about the publication of the trial data in a reputable medical journal. These
robust scientific results support the positive feedback and anecdotal
evidence we have had from many Arthrem(R) customers. Now that Arthrem(R) is
clinically proven, medical professionals are more likely to consider
recommending it as a treatment option for osteoarthritis. Publication of the
results will also enable Promisia to register Arthrem(R) as a listed
complementary medicine in Australia."
For further information please contact:
Mr Charles Daily, Chief Executive Officer 04 894 8524 or 021 643 906
Dr Sheena Hunt, Principal Scientist 04 894 8524 or 021 2016104
ENDS
End CA:00274812 For:PIL Type:GENERAL Time:2015-12-08 14:51:34
